BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paes BA, Mitchell I, Banerji A, Lanctôt KL, Langley JM. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J 2011;18:e10-9. [PMID: 21499597 DOI: 10.1155/2011/493056] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 McCutcheon KM, Jordan R, Mawhorter ME, Noton SL, Powers JG, Fearns R, Cihlar T, Perron M. The Interferon Type I/III Response to Respiratory Syncytial Virus Infection in Airway Epithelial Cells Can Be Attenuated or Amplified by Antiviral Treatment. J Virol 2016;90:1705-17. [PMID: 26608311 DOI: 10.1128/JVI.02417-15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
2 Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctôt KL; CARESS investigators. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. Pediatr Infect Dis J 2015;34:e290-7. [PMID: 26780032 DOI: 10.1097/INF.0000000000000922] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
3 Paes B, Carbonell-estrany X. Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right? Expert Review of Anti-infective Therapy 2019;17:211-22. [DOI: 10.1080/14787210.2019.1581062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bayon JL, Lina B, Rosa-calatrava M, Boivin G. Recent developments with live-attenuated recombinant paramyxovirus vaccines: Recombinant paramyxovirus vaccines. Rev Med Virol 2013;23:15-34. [DOI: 10.1002/rmv.1717] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
5 van Beek D, Paes B, Bont L. Increased risk of RSV infection in children with Down's syndrome: clinical implementation of prophylaxis in the European Union. Clin Dev Immunol 2013;2013:801581. [PMID: 23878586 DOI: 10.1155/2013/801581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
6 Cetinkaya M, Oral TK, Karatekin S, Cebeci B, Babayigit A, Yesil Y. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis. Eur J Clin Microbiol Infect Dis 2017;36:1629-34. [PMID: 28391538 DOI: 10.1007/s10096-017-2976-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Santibanez P, Gooch K, Vo P, Lorimer M, Sandino Y. Acute care utilization due to hospitalizations for pediatric lower respiratory tract infections in British Columbia, Canada. BMC Health Serv Res 2012;12:451. [PMID: 23217103 DOI: 10.1186/1472-6963-12-451] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
8 Borse RH, Singleton RJ, Bruden DT, Fry AM, Hennessy TW, Meltzer MI. The Economics of Strategies to Reduce Respiratory Syncytial Virus Hospitalizations in Alaska. J Pediatric Infect Dis Soc 2014;3:201-12. [PMID: 26625383 DOI: 10.1093/jpids/pit072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
9 Murray J, Saxena S, Sharland M. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals. Arch Dis Child 2014;99:469-73. [PMID: 24464977 DOI: 10.1136/archdischild-2013-303764] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
10 German P, Xin Y, Chien JW, Weng W, Mackman R, Lewis SA, Meng A, Ling J, Mathias A. Phase 1 First-in-Human, Single- and Multiple-Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection. J Clin Pharmacol 2018;58:1025-34. [PMID: 29663420 DOI: 10.1002/jcph.1112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
11 Drazdienė N, Laan M, Zaikauskienė J, Usonis V. Respiratory syncytial virus infection in a selected sample of infants hospitalized for lower respiratory tract infection in Lithuania and Estonia. Acta Med Litu 2017;24:191-8. [PMID: 29487482 DOI: 10.6001/actamedica.v24i4.3614] [Reference Citation Analysis]
12 Castillo LM, Bugarin G, Arias JC, Barajas Rangel JI, Serra ME, Vain N. One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America. Jornal de Pediatria 2017;93:467-74. [DOI: 10.1016/j.jped.2016.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
13 Kim GY, Rheem I, Joung YH, Kim JK. Investigation of occurrence patterns of respiratory syncytial virus A and B in infected-patients from Cheonan, Korea. Respir Res 2020;21:191. [PMID: 32682419 DOI: 10.1186/s12931-020-01456-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Blake SM, Tanaka D, Bendz LM, Staebler S, Brandon D. Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus. Adv Neonatal Care 2017;17:292-8. [PMID: 27926583 DOI: 10.1097/ANC.0000000000000367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
15 Riccò M, Ferraro P, Peruzzi S, Zaniboni A, Ranzieri S. Respiratory Syncytial Virus: Knowledge, Attitudes and Beliefs of General Practitioners from North-Eastern Italy (2021). Pediatric Reports 2022;14:147-65. [DOI: 10.3390/pediatric14020021] [Reference Citation Analysis]
16 Zandi M, Soltani S, Fani M, Abbasi S, Ebrahimi S, Ramezani A. Severe acute respiratory syndrome coronavirus 2 and respiratory syncytial virus coinfection in children. Osong Public Health Res Perspect 2021;12:286-92. [PMID: 34719220 DOI: 10.24171/j.phrp.2021.0140] [Reference Citation Analysis]
17 Fitzpatrick T, McNally JD, Stukel TA, Kwong JC, Wilton AS, Fisman D, Guttmann A. Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017. Arch Dis Child 2021;106:173-9. [PMID: 32859612 DOI: 10.1136/archdischild-2020-319472] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Demont C, Petrica N, Bardoulat I, Duret S, Watier L, Chosidow A, Lorrot M, Kieffer A, Lemaitre M. Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect Dis 2021;21:730. [PMID: 34340679 DOI: 10.1186/s12879-021-06399-8] [Reference Citation Analysis]
19 Norris MJ, Malhi M, Duan W, Ouyang H, Granados A, Cen Y, Tseng YC, Gubbay J, Maynes J, Moraes TJ. Targeting Intracellular Ion Homeostasis for the Control of Respiratory Syncytial Virus. Am J Respir Cell Mol Biol 2018;59:733-44. [PMID: 30095982 DOI: 10.1165/rcmb.2017-0345OC] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
20 Huntjens DRH, Ouwerkerk-Mahadevan S, Brochot A, Rusch S, Stevens M, Verloes R. Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects. Clin Pharmacokinet 2017;56:1331-42. [PMID: 28238203 DOI: 10.1007/s40262-017-0522-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
21 Friedman D, Fryzek J, Jiang X, Bloomfield A, Ambrose CS, Wong PC. Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses. PLoS One 2017;12:e0172512. [PMID: 28253361 DOI: 10.1371/journal.pone.0172512] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
22 Del Vecchio A, Ferrara T, Maglione M, Capasso L, Raimondi F. New perspectives in Respiratory Syncitial Virus infection. The Journal of Maternal-Fetal & Neonatal Medicine 2013;26:55-9. [DOI: 10.3109/14767058.2013.831282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
23 Volling C, Hassan K, Mazzulli T, Green K, Al-Den A, Hunter P, Mangat R, Ng J, McGeer A. Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study. BMC Infect Dis 2014;14:665. [PMID: 25494918 DOI: 10.1186/s12879-014-0665-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
24 Tawar RG, Colpitts CC, Lupberger J, El-Saghire H, Zeisel MB, Baumert TF. Claudins and pathogenesis of viral infection. Semin Cell Dev Biol 2015;42:39-46. [PMID: 25960372 DOI: 10.1016/j.semcdb.2015.04.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
25 Bhattacharya S, Agarwal S, Shrimali NM, Guchhait P. Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases. Mol Aspects Med 2021;:101000. [PMID: 34294412 DOI: 10.1016/j.mam.2021.101000] [Reference Citation Analysis]
26 Bracht M, Basevitz D, Cranis M, Paulley R. Impact of respiratory syncytial virus: the nurse's perspective. Drugs R D 2011;11:215-26. [PMID: 21902285 DOI: 10.2165/11593140-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
27 Xu R, Fathima P, Strunk T, de Klerk N, Snelling TL, Richmond PC, Keil AD, Moore HC. RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study. BMC Pediatr 2020;20:490. [PMID: 33092566 DOI: 10.1186/s12887-020-02390-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Mosalli R, Abdul Moez AM, Janish M, Paes B. Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants: Predicting RSV Hospitalization in Term Infants. J Med Virol 2015;87:1285-91. [DOI: 10.1002/jmv.24189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
29 Lu X, McCoy KS, Xu J, Hu W, Chen H, Jiang K, Han F, Chen P, Wang Y. Galectin-9 ameliorates respiratory syncytial virus-induced pulmonary immunopathology through regulating the balance between Th17 and regulatory T cells. Virus Res 2015;195:162-71. [PMID: 25451068 DOI: 10.1016/j.virusres.2014.10.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
30 Xu R, Fathima P, Strunk T, de Klerk N, Snelling TL, Richmond PC, Keil AD, Moore HC. RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study. BMC Pediatr 2020;20:490. [PMID: 33092566 DOI: 10.1186/s12887-020-02390-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Andreano E, Paciello I, Bardelli M, Tavarini S, Sammicheli C, Frigimelica E, Guidotti S, Torricelli G, Biancucci M, D'Oro U, Chandramouli S, Bottomley MJ, Rappuoli R, Finco O, Buricchi F. The respiratory syncytial virus (RSV) prefusion F-protein functional antibody repertoire in adult healthy donors. EMBO Mol Med 2021;13:e14035. [PMID: 33998144 DOI: 10.15252/emmm.202114035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Lim DK, Jeon JS, Jang TS, Kim JK. Association between climatic factors and respiratory syncytial virus detection rates in Cheonan, Korea. Environ Sci Pollut Res Int 2021. [PMID: 34585349 DOI: 10.1007/s11356-021-16546-y] [Reference Citation Analysis]
33 Drazdienė N, Tamelienė R, Kviluna D, Saik P, Saik E, Zaikauskienė J. Hospitalisation of late preterm infants due to lower respiratory tract infections in Lithuania, Latvia, and Estonia: incidence, disease severity, and risk factors. Acta Med Litu 2018;25:76-85. [PMID: 30210241 DOI: 10.6001/actamedica.v25i2.3760] [Reference Citation Analysis]
34 Buchan SA, Chung H, Karnauchow T, McNally JD, Campitelli MA, Gubbay JB, Katz K, McGeer AJ, Richardson DC, Richardson SE, Simor A, Smieja M, Zahariadis G, Tran D, Crowcroft NS, Rosella LC, Kwong JC. Characteristics and Outcomes of Young Children Hospitalized With Laboratory-confirmed Influenza or Respiratory Syncytial Virus in Ontario, Canada, 2009-2014. Pediatr Infect Dis J 2019;38:362-9. [PMID: 30882725 DOI: 10.1097/INF.0000000000002164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Elawar F, Oraby AK, Kieser Q, Jensen LD, Culp T, West FG, Marchant DJ. Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis. Pharmacol Ther 2021;220:107712. [PMID: 33121940 DOI: 10.1016/j.pharmthera.2020.107712] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Hoover J, Eades S, Lam WM. Pediatric Antiviral Stewardship: Defining the Potential Role of Ribavirin in Respiratory Syncytial Virus-Associated Lower Respiratory Illness. J Pediatr Pharmacol Ther 2018;23:372-8. [PMID: 30429691 DOI: 10.5863/1551-6776-23.5.372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
37 Alharbi AS, Alqwaiee M, Al-Hindi MY, Mosalli R, Al-Shamrani A, Alharbi S, Yousef A, Al Aidaroos A, Alahmadi T, Alshammary A, Miqdad A, Said Y, Alnemri A. Bronchiolitis in children: The Saudi initiative of bronchiolitis diagnosis, management, and prevention (SIBRO). Ann Thorac Med 2018;13:127-43. [PMID: 30123331 DOI: 10.4103/atm.ATM_60_18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
38 Morris SE, Pitzer VE, Viboud C, Metcalf CJ, Bjørnstad ON, Grenfell BT. Demographic buffering: titrating the effects of birth rate and imperfect immunity on epidemic dynamics. J R Soc Interface 2015;12:20141245. [PMID: 25589567 DOI: 10.1098/rsif.2014.1245] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
39 Mitchell I, Defoy I, Grubb E. Burden of Respiratory Syncytial Virus Hospitalizations in Canada. Can Respir J 2017;2017:4521302. [PMID: 29311757 DOI: 10.1155/2017/4521302] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
40 Marr N, Hirschfeld AF, Lam A, Wang S, Lavoie PM, Turvey SE. Assessment of genetic associations between common single nucleotide polymorphisms in RIG-I-like receptor and IL-4 signaling genes and severe respiratory syncytial virus infection in children: a candidate gene case-control study. PLoS One 2014;9:e100269. [PMID: 24949794 DOI: 10.1371/journal.pone.0100269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
41 Newby B, Sorokan T. Respiratory Syncytial Virus Infection Rates with Limited Use of Palivizumab for Infants Born at 29 to 31+6/7 Weeks Gestational Age. Can J Hosp Pharm 2017;70:13-8. [PMID: 28348428 DOI: 10.4212/cjhp.v70i1.1623] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
42 French CE, McKenzie BC, Coope C, Rajanaidu S, Paranthaman K, Pebody R, Nguyen-Van-Tam JS, Higgins JP, Beck CR; Noso-RSV Study Group. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. Influenza Other Respir Viruses 2016;10:268-90. [PMID: 26901358 DOI: 10.1111/irv.12379] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
43 Fitzpatrick T, McNally JD, Stukel TA, Kwong JC, Wilton AS, Fisman D, Guttmann A. Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017. Arch Dis Child 2021;106:173-9. [PMID: 32859612 DOI: 10.1136/archdischild-2020-319472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Pribut N, Kaiser TM, Wilson RJ, Jecs E, Dentmon ZW, Pelly SC, Sharma S, Bartsch PW 3rd, Burger PB, Hwang SS, Le T, Sourimant J, Yoon JJ, Plemper RK, Liotta DC. Accelerated Discovery of Potent Fusion Inhibitors for Respiratory Syncytial Virus. ACS Infect Dis 2020;6:922-9. [PMID: 32275393 DOI: 10.1021/acsinfecdis.9b00524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Pisesky A, Benchimol EI, Wong CA, Hui C, Crowe M, Belair MA, Pojsupap S, Karnauchow T, O'Hearn K, Yasseen AS 3rd, McNally JD. Incidence of Hospitalization for Respiratory Syncytial Virus Infection amongst Children in Ontario, Canada: A Population-Based Study Using Validated Health Administrative Data. PLoS One 2016;11:e0150416. [PMID: 26958849 DOI: 10.1371/journal.pone.0150416] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
46 Niya MHK, Jeda AS, Tavakoli A, Sohani H, Tameshkel FS, Panahi M, Izadi M, Zamani F, Keyvani H. Molecular epidemiology of human respiratory syncytial virus (HRSV) in Iranian military trainees with acute respiratory symptoms in 2017. Iran J Microbiol 2020;12:495-502. [PMID: 33604006 DOI: 10.18502/ijm.v12i5.4612] [Reference Citation Analysis]